Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 100/100

Failure Rate

33.3%

1 terminated/withdrawn out of 3 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
3(100.0%)
3Total
Phase 1(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT05127811Phase 1Terminated

A Phase I Study of ZN-d5 in Chinese Subjects With Non-Hodgkin Lymphoma

Role: lead

NCT04852419Phase 1Completed

A PHASE 1B STUDY OF ZN-C5 IN CHINESE SUBJECTS

Role: lead

NCT04972422Phase 1Unknown

A Phase 1b Study of ZN-c3 in Chinese Subjects

Role: lead

All 3 trials loaded